(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight - 2Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- 3Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- 4Help Your Business with Master Web based Promoting Arrangements
- 5Scientists found tryptophan, the ‘sleepy’ amino acid, in an asteroid. Here’s what it means
- Figure out How to Explore Land Close to 5G Pinnacles
- 5 Instructive Toy Brands for Youngsters
- A definitive Cruiser Standoff: Decision in favor of Your #1 Ride
- Terminal cancer diagnosis announced by JFK's granddaughter
- Most loved Fish Dish: What's Your Sea Pleasure?
- Physicists and philosophers have long struggled to understand the nature of time: Here's why
- Is Chinese food truly flavorful?
- Audits of 6 American Busssiness Class Flights
- Dominating the Remote Work Way of life: Individual Systems
